Complete Filing Data
Cardiol Therapeutics Inc. reported Cash And Cash Equivalents of $34.93 million for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Cardiol Therapeutics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue From Interest | $2.0M | $1.2M | $106.0K | $76.6K |
| Research And Development Expense | $14.2M | $19.0M | $10.9M | $10.6M |
| Profit Loss From Operating Activities | -$29.8M | -$41.3M | -$38.7M | -$20.7M |
| Profit Loss | -$28.1M | -$30.9M | -$31.6M | -$20.6M |
| General And Administrative Expense | $15.6M | $22.4M | $27.9M | $10.1M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Cash And Cash Equivalents | $34.9M | $59.5M | $83.9M | $14.0M | $7.0M |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $64.3K | $74.7K | $12.9K | $40.6K | |
| Cash Flows From Used In Operating Activities | -$25.2M | -$27.2M | -$23.5M | -$9.1M | |
| Cash Flows From Used In Investing Activities | -$64.3K | -$74.7K | -$12.9K | -$40.6K | |
| Cash Flows From Used In Financing Activities | -$55.4K | -$53.9K | $93.4M | $16.3M | |
| Adjustments For Increase Decrease In Trade And Other Payables | -$1.3M | $4.5M | $2.4M | $1.8M | |
| Adjustments For Decrease Increase In Trade Account Receivable | $67.2K | -$144.2K | -$59.9K | $5.9K | |
| Adjustments For Decrease Increase In Other Operating Receivables | $133.1K | $71.1K | -$127.3K | $702.1K | |
| Adjustments For Accretion Of Lese Liability | $15.9K | $9.2K | $12.9K | $16.3K | |
| Amortisation Intangible Assets Other Than Goodwill | $84.4K | $84.4K | $84.4K | $84.4K | |
| Unrealized Foreign Exchange Gain Loss On Cash Operating Activities | -$762.0K | -$2.9M | $11.1K | $56.0K | |
| Trade And Other Current Payables | $8.0M | $9.3M | $4.9M | ||
| Retained Earnings | -$142.6M | -$114.4M | -$83.5M | ||
| Other Current Receivables | $137.1K | $270.3K | $341.4K | ||
| Noncurrent Lease Liabilities | $158.5K | $22.4K | $72.9K | ||
| Liabilities | $8.5M | $9.8M | $11.6M | ||
| Impact Of Foreign Exchange On Cash And Cash Equivalents | $762.0K | $2.9M | -$11.1K | -$56.0K | |
| Equity And Liabilities | $36.7M | $62.0M | $87.9M | ||
| Current Trade Receivables | $142.7K | $209.9K | $65.7K | ||
| Current Liabilities | $8.3M | $9.8M | $11.6M | ||
| Current Lease Liabilities | $15.8K | $50.4K | $44.7K | ||
| Current Assets | $36.2M | $61.4M | $87.1M | ||
| Assets | $36.7M | $62.0M | $87.9M | ||
| Property Plant And Equipment | $295.7K | $356.5K | |||
| Issue Of Equity | $72.5M | $17.3M | |||
| Intangible Assets And Goodwill | $210.4K | $294.8K | $379.2K | ||
| Increase Decrease From Fair Value Of Warrants Earned Equity | $1.4M | $83.4K | $79.0K | ||
| Current Derivative Financial Liabilities | $238.2K | $419.9K | $6.7M | ||
| Increase Decrease Through Exercise Of Warrants Equity | $11.8M | $183.7K | |||
| Increase From Issuance Of Warrants Equity | $8.1K | ||||
| Property Plant And Equipment Including Rightofuse Assets | $337.1K | $295.7K | |||
| Adjustments For Decrease Increase In Prepaid Inventory | $4.7M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Proceeds From Issuing Shares | 84.1M | 17.3M | ||
| Payments For Share Issue Costs | $5.2M | $1.1M | ||
| Payments Of Lease Liabilities Classified As Financing Activities | $55.4K | $53.9K | $51.9K | $50.5K |
| Increase Decrease In Cash And Cash Equivalents | -$25.3M | -$27.3M | $69.9M | $7.1M |
| Proceeds From Exercise Of Options | $2.8M | |||
| Proceeds From Warrants Exercised | $11.8M | $183.7K | ||
| Proceeds From Issuance Of Warrants Net Of Issuance Costs | $8.1K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Weighted Average Shares | 64.5M | 62.5M | 43.2M | 29.9M |
| Diluted Earnings Loss Per Share | $-0.44 | $-0.49 | $-0.73 | $-0.69 |
| Basic Earnings Loss Per Share | $-0.44 | $-0.49 | $-0.73 | $-0.69 |
| Adjusted Weighted Average Shares | 64.5M | 62.5M | 43.2M | 29.9M |
| Increase From Shares Issued For Services Equity | 16.4K | 525.2K | 4.1M | 49.7K |
| Adjustments For Shares Issued For Services | 16.4K | 525.2K | 4.1M | 49.7K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Increase Decrease Through Sharebased Payment Transactions | $4.2M | $5.0M | $8.5M | $2.8M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$712.7K | $2.8M | $1.9M | -$34.5K |
| Adjustments For Sharebased Payments | $4.2M | $5.0M | $8.5M | $2.8M |
| Adjustments For Depreciation Expense | $163.9K | $135.5K | $136.0K | $145.1K |
| Adjustments For Decrease Increase In Prepaid Expenses | $546.5K | $1.3M | -$2.1M | -$64.1K |
| Other Income | $149.7K | $164.4K | $112.2K | $7.4K |
| Issued Capital | $148.5M | $147.5M | $142.9M | |
| Share Premium | $18.8M | $15.6M | $12.7M | |
| Gains Losses On Change In Fair Value Of Derivatives | $181.7K | $6.2M | $4.9M | |
| Current Prepaid Expenses | $941.4K | $1.5M | $2.8M | |
| Adjustments For Gains Losses On Change In Fair Value Of Derivatives | $181.7K | $6.2M | $4.9M | |
| Share Issue Related Cost | $5.2M | $1.1M | ||
| Warrant Reserve | $3.5M | $3.5M | $4.2M | |
| Adjustments For Expenses To Be Settled Through Warrant Exercise | $1.4M | $83.4K | $79.0K | |
| Increase Decrease Through Exercise Of Options | $2.8M | |||
| Adjustments For Decrease Increase In Inventories | $18.0K | $1.1M |
Most recent annual filing with the SEC: April 1, 2024
Data sourced from SEC EDGAR public filings as of August 6, 2026.